Fig. 3.

Inhibition of IDO1 represses cardiac hypertrophy in vivo. a PF-06840003 reduces IDO1 activity in mouse hearts. Mice were treated with IDO1 inhibitor PF-06840003 (200 mg/kg/day, i.p.) for 14 days. n = 5 in each group. **p < 0.01 by Student’s t test. b Fraction shortening, ejection fraction, and left wall thickness of mice. Cardiac hypertrophy was induced by subcutaneously chronic infusion of Ang II (1.3 mg/kg/day) for 14 days in the presence or absence of IDO1 inhibitor PF-06840003 (200 mg/kg/day, i.p.). Ang II, angiotensin II. n = 5 in each group. **p < 0.01 by Student’s t test. n = 5 in each group. **p < 0.01 by one-way ANOVA followed by Turkey post-hoc test. c Heart weight-to-body weight ratio of mice with/without cardiac hypertrophy (b). n = 5 in each group. **p < 0.01 by one-way ANOVA followed by Turkey post-hoc test. d Haematoxylin and eosin (H&E) staining shows the increased cardiomyocyte size in mice with cardiac hypertrophy. n = 5 in each group. **p < 0.01 by one-way ANOVA followed by Turkey post-hoc test. e qRT-PCR shows the expression of hypertrophic genes in control and hypertrophic hearts in mice. n = 5 in each group. **p < 0.01 by one-way ANOVA followed by Turkey post-hoc test